| Base-case | DSA | PSA | ||||||
---|---|---|---|---|---|---|---|---|---|
 | HZ | PHN | HZ | PHN |  | ||||
Epidemiology[21] | |||||||||
Age-group | Cases/1,000 PY | % of HZ-cases | 95% CI (Cases/1,000 PY) | 95% CI (% of HZ-cases) | Triangular | ||||
50–59 | 6.56 | 3.38 | 6.12–7.01 | 2.15–4.61 |  | ||||
60–69 | 9.19 | 4.92 | 8.68–9.71 | 3.73–6.11 |  | ||||
70–79 | 11.24 | 7.85 | 11.66–11.82 | 6.48–9.23 |  | ||||
>80 | 12.76 | 7.8 | 11.92–13.61 | 6.05–9.55 |  | ||||
Age-group | Â | Â | 95%Â CI | 95%Â CI | Beta | ||||
50–59 | 69.8 | 65.7* | 54.1–80.6 | 20.4*–86.7* |  | ||||
60–64 | 65.4 | 65.7 | 55–70.9 | 20.4–86.7 |  | ||||
65–69 | 62.58 | 65.7 | 55–70.9 | 20.4–86.7 |  | ||||
70–74 | 43.74 | 66.8 | 25–48.1 | 43.3–81.3 |  | ||||
75–79 | 36.51 | 66.8 | 25–48.1 | 43.3–81.3 |  | ||||
80–84 | 20.09 | 66.8 | 25–48.1 | 43.3–81.3 |  | ||||
>85 | 13.22 | 66.8 | 25–48.1 | 43.3–81.3 |  | ||||
EQ-5D utilitiesª[14] | |||||||||
Age-group | Â | Â | 95%Â CI | 95%Â CI | Beta | ||||
50–60 | 0.68 | 0.725 | 0.61–0.745 | 0.63–0.815 |  | ||||
61–70 | 0.6 | 0.68 | 0.525–0.67 | 0.605–0.76 |  | ||||
>70 | 0.62 | 0.64 | 0.550.69 | 0.57–0.705 |  | ||||
Treatment costs per case (€)[21] | |||||||||
Perspectives/Age-group | Payer | Societal | Payer | Societal | Payer 95% CI | Societal 95% CI | Payer 95% CI | Societal 95% CI | Gamma |
50–59 | 193 | 570 | 872 | 1,339 | 148–245 | 495–651 | 289–1,940 | 436–3,065 |  |
60–69 | 226 | 338 | 1,349 | 2,137 | 179–270 | 281–397 | 714–2,125 | 975–3,625 |  |
70–79 | 203 | 214 | 1,172 | 1,218 | 159–252 | 169–263 | 717–1,785 | 750–1,863 |  |
>80 | 320 | 331 | 642 | 676 | 249–394 | 259–408 | 251–1,157 | 270–1,207 |  |
 | Background mortality [probability (%) p.a.]***[48] | HZ related mortality [deaths/100,000 PY]***[22] | |||||||
Age-group | Â | Â | Â | Â | Â | Â | Â | Â | Â |
50–59 |  |  | 0.7 |  |  |  | 0.02 |  |  |
60–69 |  |  | 1.5 |  |  |  | 0.09 |  |  |
70–79 |  |  | 3.9 |  |  |  | 0.42 |  |  |
80–89 |  |  | 11 |  |  |  | 2.53 |  |  |
90–99 |  |  | 26.2 |  |  |  | 3.86 |  |  |
100+ | Â | Â | 56.8 | Â | Â | Â | 3.86 | Â | Â |
Other input parameter | |||||||||
 | Base-case | DSA [lower/higher value] | PSA | ||||||
Vaccine Price/dose (€)[59] | 140.48 | 70.24 | 210.72 | Normal | |||||
Vaccine administration costs (€)** | 7 | 5.20 | 10.81 | Normal | |||||
Discount rate (% p.a.) | 3 | 0 | 10 | Â | |||||
Waning immunity rate (% p.a.)[56] | 8.3 | 0 | 20 | Beta | |||||
Coverage (%) assumption | 20 | - | - | Â | |||||
HZ susceptibility**** (%)[2] | 100 | - | - | Â | |||||
EQ-5D utilities for healthy individuals (age in years) | 1(all ages) | 0.859b (41–60) | 0.7684b (61+) |  |